SPRAVATO® (esketamine) approved in the U.S. as the first and …
2 days ago · Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive ...
Janssen Announces U.S. FDA Approval of SPRAVATO - Johnson & Johnson
TITUSVILLE, N.J. – (August 3, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults ...
SPRAVATO® (esketamine) approved in the U.S. as the first and …
2 days ago · Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray ...
Janssen Announces U.S. FDA Approval of SPRAVATO - Johnson & Johnson
TITUSVILLE, N.J., – (March 5, 2019) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved SPRAVATO™ (esketamine) CIII nasal spray for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD). 1 People who are currently ...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine…
Titusville, New Jersey, July 22, 2024 – Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO®(esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine…
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried...
FDA approves first-of-its-kind nasal spray for severe depression
Spravato is now cleared to use by itself after years of clinical trials. By Andrew Paul Posted 24 Hours Ago Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine ...
SPRAVATO® (esketamine) approved in the U.S. as the first and …
2 days ago · TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive ...
Johnson & Johnson ketamine-derived nasal spray gets FDA …
1 day ago · Johnson & Johnson beat analyst expectations for revenue by $70 million, but highlighted possible negative impacts in its outlook from an ongoing talc lawsuit and slower medical device sales.
- Some results have been removed